GLP-1 and GLP-2 receptor co-agonist
Dapiglutide 4 mg injection once weekly
DAPIGL_SC_4MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.38 (0.00 to 19.47) | 0.67 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.62 (0.60 to 4.64) | 0.78 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.56 (0.28 to 10.59) | 0.75 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.07 (0.54 to 9.12) | 0.46 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.33 (0.21 to 7.76) | 0.62 |